3-Ethoxybenzamide
Based on 1 Customer Validation
3-Ethoxybenzamide is an alkoxybenzamide compound with antibacterial activity and a FtsZ inhibitor that can cross the blood-brain barrier. 3-Ethoxybenzamide distributes widely and rapidly in vivo, rapidly reaches equilibrium between various tissues and blood, and is linearly taken up by hepatocytes. 3-Ethoxybenzamide is completely dependent on hepatic microsomal oxidation for clearance, with salicylamide as its major metabolite. 3-Ethoxybenzamide can be used for the study of bacterial infections.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 55836-69-6
- Formel: C9H11NO2
- Molecular Weight:165.19
-
Speicherung:
Store at room temperature 3 years.
In solvent -80°C, 2 years , -20°C, 1 year
Biologische Aktivität
Beschreibung
In Vitro
3-Ethoxybenzamide (0.1-1.0 mM; 0.5-10 min) rapidly reaches equilibrium with rat erythrocytes, and its whole blood-plasma partition coefficient equals 1 at all tested concentrations[1].
3-Ethoxybenzamide undergoes deethylation in rat liver microsomes, with the corrected kinetic parameter being Vmax1=0.124 μmol/min/g[1].
3-Ethoxybenzamide (500-2000 μg/mL) inhibits the bacterial growth of Bacillus subtilis 168, with an MIC of 2000 μg/mL, and induces cell division inhibition at a concentration of 500 μg/mL[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Staphylococcus aureus, Bacillus subtilis 168
-
Concentration:500-2000 μg/mL
-
Incubation Time:/
-
Result:Against Staphylococcus aureus and Bacillus subtilis 168 with MIC of 1024 μg/mL and 2000 μg/mL, respectively.
In Vivo
3-Ethoxybenzamide (20-100 mg/kg; i.v.; single bolus) simulated plasma and tissue concentrations in healthy 250 g rats show reasonable agreement with observed values across 20 mg/kg, 50 mg/kg, and 100 mg/kg intravenous bolus doses, with minor discrepancies in small intestine and muscle tissue profiles[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:albino (male, 1.7-2.3 kg)[1]
-
Dosage:10 mg/kg; 20 mg/kg; 80 mg/kg
-
Administration:i.v.; single bolus
-
Result:Showed very good agreement between simulated and observed plasma concentrations at 10 mg/kg and 20 mg/kg doses.
Systemically higher observed plasma concentrations than simulated values in the terminal elimination phase at 80 mg/kg dose.
Showed general agreement between simulated and observed tissue concentrations in brain, kidney, and liver at 20 mg/kg dose, despite some variability in measured tissue levels.
-
Animal Model:250 g body weight[1]
-
Dosage:20 mg/kg; 50 mg/kg; 100 mg/kg
-
Administration:i.v.; single bolus
-
Result:Predicted observed rat plasma data reasonably well with simulated plasma concentration-time profiles at 20 mg/kg, 50 mg/kg, and 100 mg/kg doses.
Showed reasonable agreement between simulated and observed tissue concentrations in most tissues (brain, lung, liver, kidney, muscle, skin, adipose) at 20 mg/kg dose.
Overestimated peak levels in simulated small intestine concentrations and showed a delayed peak not seen in observed data in simulated muscle concentrations at 20 mg/kg dose.
Chemical Information
-
CAS. Nr. 55836-69-6
-
Appearance Solid
-
Molecular Weight 165.19
-
Formel C9H11NO2
-
Color White to off-white
-
SMILES
O=C(N)C=1C=CC=C(OCC)C1
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Store at room temperature 3 years
In solvent -80°C 2 years -20°C 1 year
Protokoll
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Protocol for Pharmacokinetic Study
Pharmacokinetic studies quantify how an organism handles a drug over time through absorption, distribution, metabolism, and excretion, and the core experimental readout is the concentration-time profile of parent drug and, when relevant, metabolites in biological matrices such as plasma, whole blood, urine, bile, or tissue. Pharmacokinetic analysis links dose, route, exposure, clearance, half-life, distribution, bioavailability, and systemic exposure to drug efficacy and toxicity hypotheses rather than measuring a signaling pathway directly. The literature links pharmacokinetics to drug-development phenotypes by showing that drug metabolism and pharmacokinetics influence compound progression, exposure-response interpretation, safety margins, dosing strategy, and failure risk during discovery and development. DMPK science contributes to compound optimization by integrating physicochemical properties, in vitro metabolism, transporter behavior, in vivo exposure, and pharmacodynamic contex
-
Bacterial live/dead nucleic-acid viability staining
The LIVE/DEAD bacterial viability staining method is based on differential permeability of nucleic-acid-binding fluorescent dyes, most commonly SYTO 9 and propidium iodide (PI), which enables discrimination of bacterial populations with intact versus compromised cytoplasmic membranes. SYTO 9 penetrates both intact and damaged bacterial membranes and binds nucleic acids to produce green fluorescence, whereas propidium iodide penetrates only cells with compromised membranes and fluoresces red while also reducing SYTO 9 signal through competitive binding and fluorescence interactions. The resulting fluorescence pattern is interpreted as a proxy for membrane integrity, which is widely used as an indicator of bacterial viability in microscopy, flow cytometry, and spectroscopic platforms. However, mechanistic studies show that SYTO 9 and PI interactions involve displacement and fluorescence resonance energy transfer effects, which can influence signal interpretation depending on dye ratios a
Reinheit & Dokumentation
Verweise
[1]. Lin JH, et al. Physiological pharmacokinetics of ethoxybenzamide based on biochemical data obtained in vitro as well as on physiological data. J Pharmacokinet Biopharm. 1982;10(6):649-661. [Content Brief]
[2]. Czaplewski LG, et al. Antibacterial alkoxybenzamide inhibitors of the essential bacterial cell division protein FtsZ. Bioorg Med Chem Lett. 2009;19(2):524-527. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)